'Smart bombs' deliver kidney cancer medication

Researchers at the Society of Nuclear Medicine in San Antonio, TX, are zapping kidney cancer cells with "smart bombs" made of a new form of radioimmunotherapy that zeroes in on antigens associated with renal cell carcinoma. The treatment is composed of medical radionuclides bound with antibodies that recognize physiological changes involved in the disease process. Once inside the body, the treatment targets cancerous tissues expressing the antigen carbonic anhydrase IX, which is associated with renal cell carcinoma. In a study, 14 of the 20 patients treated were able to reach stabilization of their cancer 12 weeks after treatment. Release

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.